

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 30 of June 2022

	30.06.2022	31.12.2021
	<i>BGN'000</i>	<i>BGN'000</i>
ASSETS		
Non-current assets		
Property, plant and equipment	36 842	38 071
Intangible assets	3 443	3 451
Investments in subsidiaries	19	19
Trade receivables	5 276	5 276
Total non-current assets	45 580	46 817
Current assets		
Inventories	8 990	11 342
Trade and other receivables	65 089	59 220
Current corporate income tax		40
Cash and cash equivalents	26	40
Total current assets	74 105	70 642
Total assets	119 685	117 459
LIABILITIES		
Equity		
Share capital	84 500	84 500
Reserves	12 522	12 382
Retained earnings	4 387	1 940
Total	101 409	98 822
Non-current liabilities		
Long-term loans	1 499	1 717
Deferred tax liabilities	1 030	1 030
Retirement benefit obligations	149	151
Total non-current liabilities	2 678	2 898
Current liabilities		
Trade and other liabilities	4 518	4 720
Short-term loans	9 783	9 781
Current portion of long-term loans	865	990
Current corporate income tax		125
Other tax liabilities	432	123
Total current liabilities	15 598	15 739
Total liabilities	18 276	18 637
Total equity and liabilities	119 685	117 459

Date of preparation: 26.07.2022

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 30 of June 2022

	30.06.2022	30.06.2021
	<i>BGN'000</i>	<i>BGN'000</i>
Revenue	22 668	22 302
Other income	313	21
Total income	22 981	22 323
Carrying amount of goods sold	(329)	(462)
Changes in inventories of finished products and work in progress	(626)	613
Materials and services	(14 294)	(14 467)
Personnel expenses	(2 769)	(2 691)
Depreciation / amortisation expenses	(1 825)	(2 037)
Other expenses	(198)	(282)
Finance income	23	11
Finance costs	(196)	(196)
Total expenses	(20 214)	(19 511)
Profit before taxation	2 767	2 812
Corporate income tax expense	(180)	(96)
Profit/Loss for the period	2 587	2 716
Total comprehensive income for the period	2 587	2 716
Earnings per share / in BGN per 1 share /	0.03	0.03

Date of preparation: 26.07.2022

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 30 of June 2022

	30.06.2022	30.06.2021
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	15 203	16 464
Payments to suppliers of materials, goods and services	(8 615)	(11 089)
Payments to personnel	(2 845)	(2 478)
Foreign exchange gains and losses	(24)	-
Payments of interest and dividends	(265)	(96)
Other proceeds / payments	(2 598)	(1 774)
Net cash flows	856	1 027
Cash flows from investing activities		
Payments on non-current assets acquired	(507)	(731)
Net cash flows	(507)	(731)
Cash flows from financial activities		
Proceeds from loans	98	82
Payments on loans	(97)	(185)
Payment of interest, dividends	(103)	(14)
Payments on finance lease	(261)	(197)
Net cash flows	(363)	(314)
<hr/>		
Change in cash and cash equivalents	(14)	(18)
Cash and cash equivalents at the beginning of the period	40	45
Cash and cash equivalents at the end of the period	26	27

Date of preparation: 26.07.2022

Sofia

Prepared by:.....

/ P. Moneva /

Executive

Director:.....

/B. Georgiev /

Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 30 of June 2022

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2021	82 200	4 088	7 944	2 904	97 136
Profit/loss for the period				1 399	1 399
Other comprehensive income		287			287
Including from tax effect of the revaluation of property, plant and equipment		(39)			(39)
Total comprehensive income		287		604	593
Issue of shares by the owners					
Dividends accrued					
Tantimmes accrued					
Profit transferred to reserves	2 300		63	(2 363)	
Total amount of income and expenses recognised during the period	2 300		63	(2 363)	
Balance as of 31.12.2021	84 500	4 375	8 007	1 940	98 822
Balance as of 01.01.2022	84 500	4 375	8 007	1 940	98 822
Profit/loss for the period				2 587	2 587
Other comprehensive income					
Total comprehensive income				2 587	2 587
Issue of shares by the owners			140	(140)	
Total amount of income and expenses recognised during the period			140	(140)	
Balance as of 30.06.2022	84 500	4 375	8 147	4 387	101 409

Date of preparation: 26.07.2022
Sofia

Prepared by:.....
/P. Moneva/

Executive Director:.....
/B. Georgiev/